Aptevo Therapeutics Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aptevo reported that 10 of 47 (21%) evaluable frontline AML patients treated with mipletamig combined with venetoclax and azacitidine advanced to allogeneic stem cell transplant, compared to 0.7% (3 of 286) in the VIALE-A trial with VEN+AZA alone. The RAINIER Phase 1b/2 dose optimization trial is expected to conclude by year-end 2026, with FDA interaction and Phase 2 initiation anticipated in H1 2027. This interim clinical data represents the company's lead candidate's progress toward potentially curative outcomes in patients initially deemed unfit for intensive chemotherapy.
Why this rating
Interim Phase 1b data showing 30× higher transplant rate than standard-of-care benchmark is materially encouraging for a $9.8M-market-cap clinical-stage biotech; validates lead program progression; de-risks path to Phase 2 and regulatory engagement, but remains early-stage with small patient numbers.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.62 ▼ 4.09% | at our read · unknown $1.69 | +10 min · unknown $1.70 ▲ 0.24% | +30 min · unknown $1.68 ▼ 0.77% | +1 hr · unknown $1.73 ▲ 2.31% | +4 hrs pending |
The stock had already moved +4.27% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.